
Opinion|Videos|September 30, 2024
Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)
Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T cell engagement and targeting malignant B cells effectively.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Provide a brief overview of the use of bispecifics antibiotics (BsAbs) in NHL
- Please give a brief overview of the four bispecific antibodies cuused in NHL
- Mosunetuzumab
- Epicortamab
- Glofitamab
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
4
Real-World Data Confirm Alectinib's Edge Over Crizotinib in ALK+ NSCLC
5





























